Autonomic nervous system disorder
MONDO:0001292A disease involving the autonomic nervous system.
Also known as: autonomic nervous disease, autonomic nervous system disease, autonomic nervous system disease or disorder, disease of autonomic nervous system, disease or disorder of autonomic nervous system, disorder of autonomic nervous system, disorder of peripheral autonomic nervous system, disorder of the autonomic nervous system
209 clinical trials for this condition and its sub-types, 59 tagged with Autonomic nervous system disorder itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Autonomic nervous system disorder
-
Dysautonomia 16 trials · 64 incl. sub-types
1 sub-type
- Primary dysautonomia 52 trials Sub-types →
-
Autonomic nervous system neoplasm 0 trials · 60 incl. sub-types
3 sub-types
- Paraganglioma 53 trials · 57 incl. sub-types Sub-types →
- Ganglioneuroma 5 trials Sub-types →
- Sympathetic neurilemmoma 0 trials
-
Sympathetic nervous system disorder 8 trials · 28 incl. sub-types
2 sub-types
- Sympathetic paraganglioma 0 trials · 16 incl. sub-types Sub-types →
- Ganglioneuroma 5 trials Sub-types →
-
Pure autonomic failure 18 trials
-
Autonomic dysreflexia 11 trials
-
Autonomic neuropathy 7 trials · 10 incl. sub-types
2 sub-types
- Diabetic autonomic neuropathy 7 trials
- Horner syndrome 0 trials Sub-types →
-
Baroreflex failure 1 trial
-
Frey syndrome 0 trials
-
Chronic hiccup 0 trials
-
Harlequin syndrome 0 trials
-
1 sub-type
- Parasympathetic paraganglioma 0 trials Sub-types →
Most studied deeper sub-types
-
Experimental kidney cancer drug trial halted early
Disease control Stopped earlyThis early-stage trial tested a new drug called DFF332, which targets a protein (HIF2α) that helps some cancers grow. The study included 40 adults with advanced clear cell renal cell carcinoma or other cancers with specific gene changes. DFF332 was tested alone and in combination…
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Experimental cancer drug tested in rare tumors, but trial stopped early
Disease control Stopped earlyThis phase 2 trial tested the drug guadecitabine (SGI-110) in people aged 12 and older with rare cancers like wild-type GIST, pheochromocytoma, paraganglioma, and HLRCC-related kidney cancer that had not responded to other treatments. Participants received daily injections for 5 …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Experimental vaccine combo for rare adrenal cancers shows early promise but trial halted
Disease control Stopped earlyThis early-phase trial tested a new therapeutic vaccine (EO2401) combined with the immunotherapy drug nivolumab in 70 people with advanced adrenocortical carcinoma or malignant pheochromocytoma/paraganglioma. The goal was to see if the combination is safe and can shrink tumors or…
Phase 1/2 • Sponsor: Enterome • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Prostate cancer Therapy's hidden heart risk: new study investigates
Knowledge-focused Stopped earlyThis study looked at 10 men to understand why androgen deprivation therapy (ADT) for prostate cancer can lead to high blood pressure. Researchers checked if problems with the nervous system or kidneys were to blame. The goal is to find ways to prevent heart disease in prostate ca…
Phase 4 • Sponsor: University of Colorado, Denver • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
Scientists probe hidden danger of low blood sugar in diabetes
Knowledge-focused Stopped earlyThis study looked at why people with type 1 diabetes often fail to sense dangerously low blood sugar (hypoglycemia). Researchers tested how opioid drugs like morphine and naloxone affect the body's ability to respond to low sugar. The goal was to better understand the problem, no…
Phase 2 • Sponsor: Albert Einstein College of Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC